Literature DB >> 17601059

[Evaluation of treatment and prognosis of Merkel cell carcinoma of the eyelid in Japan].

Eriko Matsushita1, Nobutsugu Hayashi, Atsuki Fukushima, Hisayuki Ueno.   

Abstract

PURPOSE: To evaluate retrospectively the management and prognosis of Merkel cell carcinoma of the eyelid in Japanese patients. SUBJECTS AND METHODS: Cases diagnosed as Merkel cell carcinoma of the eyelid from January 1993 to February 2005 in 111 institutions in Japan were included in this retrospective study. Management and prognosis were evaluated.
RESULTS: The total number of cases enrolled was 21(5 male and 16 female patients). Excision of the tumor was carried out in 18 cases. Two cases were treated with either irradiation or local injection of interferon after biopsy of the tumor. After initial treatment, there were recurrences in 3 cases; local recurrence in one case and nodal metastasis in two cases. No patient died because of Merkel cell carcinoma of the eyelid.
CONCLUSIONS: Excision with wide surgical margins with irradiation is recommended as the first choice of treatment for Merkel cell carcinoma of the eyelid. Because the number of patients was only 21 and the duration of observation was short, further investigation is necessary to determine the optimal management and more accurate prognosis for Merkel cell carcinoma.

Entities:  

Mesh:

Year:  2007        PMID: 17601059

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  4 in total

1.  Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.

Authors:  Kelly G Paulson; Andrew Tegeder; Christoph Willmes; Jayasri G Iyer; Olga K Afanasiev; David Schrama; Shinichi Koba; Renee Thibodeau; Kotaro Nagase; William T Simonson; Aaron Seo; David M Koelle; Margaret Madeleine; Shailender Bhatia; Hideki Nakajima; Shigetoshi Sano; James S Hardwick; Mary L Disis; Michele A Cleary; Jürgen C Becker; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-08-12       Impact factor: 11.151

2.  The role of the immune response in merkel cell carcinoma.

Authors:  Pierre L Triozzi; Anthony P Fernandez
Journal:  Cancers (Basel)       Date:  2013-02-28       Impact factor: 6.639

3.  Merkel cell carcinoma in Taiwan: A series of 24 cases and literature review.

Authors:  John Wen-Cheng Chang; Yao-Yu Chang; Yen-Lin Huang; Yun-Feng Lo; Tsung-Ying Ho; Yi-Ting Huang; Huan-Wu Chen; Chun-Nan Yeh; Chiao-En Wu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

4.  A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan.

Authors:  Wen-Cheng Chang; Amy Y Lin; Jason C Hsu; Chiao-En Wu; Connie Goh; Patrick Chou; Kaitlin Kuo; Anne Chang; Roberto Palencia
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.